
ONO-7475
CAS No. 1646839-59-9
ONO-7475 ( —— )
产品货号. M21626 CAS No. 1646839-59-9
ONO-7475 是一种对 anexelekto 和 MER 酪氨酸激酶具有高特异性的抑制剂。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥1126 | 有现货 |
![]() ![]() |
10MG | ¥1798 | 有现货 |
![]() ![]() |
25MG | ¥3046 | 有现货 |
![]() ![]() |
50MG | ¥4528 | 有现货 |
![]() ![]() |
100MG | ¥6367 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称ONO-7475
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述ONO-7475 是一种对 anexelekto 和 MER 酪氨酸激酶具有高特异性的抑制剂。
-
产品描述ONO-7475?is an inhibitor with high specificity for anexelekto and MER tyrosine kinase.
-
体外实验Cell Viability Assay Cell Line:High AXL-expressing cell: PC-9,HCC4011,H1975, PC-9KGR cellsLow AXL-expressing cell: HCC827, HCC4006, and H3255 cells Concentration:0.0001 μM; 0.001 μM; 0.01 μM; 0.1 μM; 1 μM Incubation Time:72 hours Result:Increased the sensitivity and efficacy to Osimertinib in AXL-high level cells.Western Blot Analysis Cell Line:PC-9, HCC4011 cells Concentration:1 μM Incubation Time:4 or 48 hours Result:Increased p-AXL, AKT, and p70S6K expression at 4 hours and increases p-PARP expression at 48 hours when combindes with Osimertinib.
-
体内实验Animal Model:Mouse CDX model using high-AXL-expressing PC-9KGR cells (exon 19 deletion and the exon21-T790M mutation in EGFR)Dosage:10 mg/kg; once daily; 19 days Administration:oral gavage Result:Had little effects alone, but combined treatments significantly decreased tumor volume without reappear.
-
同义词——
-
通路Tyrosine Kinase
-
靶点TAM Receptor
-
受体Mer
-
研究领域——
-
适应症——
化学信息
-
CAS Number1646839-59-9
-
分子量562.57
-
分子式C32H26N4O6
-
纯度>98% (HPLC)
-
溶解度DMSO:100 mg/mL (177.76 mM)
-
SMILESCOc1cc2nccc(Oc3ccc(NC(=O)c4cc5C(=O)CCCc5n(-c5ccccc5)c4=O)nc3)c2cc1OC
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Ruvolo PP et al. Anexelekto/MER tyrosine kinase?inhibitor?ONO-7475?arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms.Haematologica.?2017 Dec;102(12):2048-2057.